Black Diamond Therapeutics, Inc. BDTX
1.81 USD +0.06 (+3.43%)
At closeNov 3, 2026, 4:01 PM EST
1.81 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
1.76 Day range 1.85
1.60 52-week range 4.94
- YTD
- -25.51%
- 1 year
- -54.18%
Analyst view
Price target (mean) 14.50 +701.1% upside
Now 1.81
- Target (low)
- 9.00
- Target (mean)
- 14.50
- Target (high)
- 20.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
- Strong buy3
- Buy4
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.31167 | -0.36 – -0.21 | -0.34 | +8.3% | 0 | 0.0% | 6 |
| Next quarter | -0.33 | -0.44 – -0.20 | -0.35 | +5.7% | 0 | 0.0% | 4 |
| Current year | -1.27 | -1.34 – -1.04 | -1.88 | +32.5% | 0 | 0.0% | 6 |
| Next year | -1.25 | -1.93 – -0.68 | -1.27 | +1.2% | 0 | 0.0% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 9, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 8, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 24, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Sep 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 10, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Jul 31, 2024 | Raymond James | Initiated | — | Outperform |
| Jul 3, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Jun 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 8, 2024 | Wedbush | Maintained | Outperform | Outperform |
| Mar 18, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 13, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 22, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 12, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Jul 14, 2023 | Piper Sandler | Initiated | — | Overweight |
| Jun 30, 2023 | Stifel | Upgrade | Hold | Buy |
| Jun 28, 2023 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Jun 27, 2023 | Stifel | Reiterated | Hold | Hold |
| Jun 27, 2023 | Wedbush | Upgrade | Neutral | Outperform |
| May 10, 2023 | Wedbush | Reiterated | — | Neutral |
| Mar 29, 2022 | Wedbush | Downgrade | Outperform | Neutral |
| Mar 22, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Mar 18, 2022 | Stifel | Maintained | — | Hold |
| Sep 30, 2021 | Stifel | Initiated | — | Hold |
| Jan 7, 2021 | Wedbush | Initiated | — | Outperform |
| Nov 24, 2020 | Berenberg | Initiated | — | Buy |